New York, NY (PRWEB) September 26, 2006
Rosenbaum Faria, LLP, a Manhattan law firm, is acting in response to a link between Fosamax and dead jaw disease.
Fosamax (alendronate sodium), an osteoporosis medication, and osteonecrosis (bone death) have been linked by reports from more than 2,400 patients. This fact was borne out on September 24, 2004, when pharmaceutical giant Merck and the USFDA issued a warning to health care professionals alerting them to this serious condition.
ONJ or “dead jawbone disease” can cause a patient’s jawbone to deteriorate and die. Painful surgery is required to remove dead and dying bone tissue. Further side effects of ONJ include jaw pain, numbness, exposed oral bones, loss of teeth, and infection. While Merck initially asserted the condition would only occur in persons undergoing chemotherapy or radiation, or in people with preexisting tooth and jaw disease, according to mounting lawsuits, reports from patients have proven otherwise.
“Merck became aware of this problem in early 2001 when the first reports starting coming in. They waited until September 2004 to issue a warning to health care professionals, and they didn’t post any warnings on their labels until 2005,” said Cory Rosenbaum, partner in Rosenbaum Faria, LLP.
“The damage to these unfortunate people's jaw and teeth is often severe, and the pain is described by some as 'unimaginable',” said Mr. Rosenbaum. “We have been speaking with people who developed dead jaw during or following their treatment with Fosamax and Fosamax Plus D.”
Rosenbaum Faria, LLP, is continuing to follow breaking news about Fosamax, osteonecrosis of the jaw (ONJ), and other relevant aspects of this serious issue. Future news about Fosamax will be posted on their website at http://www.coryrosenbaum.com for review by all visitors.
In Re: Fosamax Products Liability Litigation
US District Court for the Southern District of NY